- Home
- MEIP vs BREA Comparison
MEIP vs BREA Comparison
Compare MEIP & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- BREA
- Stock Information
- Founded
- MEIP 2000
- BREA 2022
- Country
- MEIP United States
- BREA Ireland
- Employees
- MEIP N/A
- BREA N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- BREA Services-Misc. Amusement & Recreation
- Sector
- MEIP Health Care
- BREA Consumer Discretionary
- Exchange
- MEIP Nasdaq
- BREA Nasdaq
- Market Cap
- MEIP 13.3M
- BREA 16.1M
- IPO Year
- MEIP 2003
- BREA 2023
- Fundamental
- Price
- MEIP $6.60
- BREA $6.57
- Analyst Decision
- MEIP Hold
- BREA
- Analyst Count
- MEIP 1
- BREA 0
- Target Price
- MEIP N/A
- BREA N/A
- AVG Volume (30 Days)
- MEIP 2.8M
- BREA 18.1K
- Earning Date
- MEIP 09-18-2025
- BREA 01-01-0001
- Dividend Yield
- MEIP N/A
- BREA N/A
- EPS Growth
- MEIP N/A
- BREA N/A
- EPS
- MEIP N/A
- BREA N/A
- Revenue
- MEIP N/A
- BREA $2,988,009.00
- Revenue This Year
- MEIP N/A
- BREA N/A
- Revenue Next Year
- MEIP N/A
- BREA N/A
- P/E Ratio
- MEIP N/A
- BREA N/A
- Revenue Growth
- MEIP 33.76
- BREA 151.51
- 52 Week Low
- MEIP $1.46
- BREA $5.00
- 52 Week High
- MEIP $9.00
- BREA $19.50
- Technical
- Relative Strength Index (RSI)
- MEIP 81.52
- BREA 46.11
- Support Level
- MEIP $5.75
- BREA $6.51
- Resistance Level
- MEIP $9.00
- BREA $7.48
- Average True Range (ATR)
- MEIP 0.85
- BREA 0.63
- MACD
- MEIP 0.39
- BREA -0.05
- Stochastic Oscillator
- MEIP 62.50
- BREA 20.20
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.